Compare ICCC & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ICCC | ICCM |
|---|---|---|
| Founded | 1982 | 2006 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.5M | 45.5M |
| IPO Year | 1987 | N/A |
| Metric | ICCC | ICCM |
|---|---|---|
| Price | $5.70 | $0.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 20.0K | ★ 385.9K |
| Earning Date | 11-13-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $27,769,304.00 | $2,975,000.00 |
| Revenue This Year | N/A | $13.67 |
| Revenue Next Year | N/A | $38.55 |
| P/E Ratio | $21.85 | ★ N/A |
| Revenue Growth | ★ 16.49 | N/A |
| 52 Week Low | $4.28 | $0.59 |
| 52 Week High | $7.60 | $1.66 |
| Indicator | ICCC | ICCM |
|---|---|---|
| Relative Strength Index (RSI) | 56.36 | 41.68 |
| Support Level | $4.72 | $0.67 |
| Resistance Level | $5.36 | $0.73 |
| Average True Range (ATR) | 0.31 | 0.04 |
| MACD | 0.13 | 0.01 |
| Stochastic Oscillator | 90.31 | 60.75 |
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.